EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs

John H McDermott iD, Videha Sharma, William G Newman, Paul Wilson, Katherine Payne, Stuart Wright

British Journal of Clinical Pharmacology · 2024-07 · 90 (7) · 1699-1710

DOI: 10.1111/bcp.16058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 14.04.2024. Verfasst von John H McDermott und 5 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, State Medicine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Innovate UK, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Genetic testing can be used to improve the safety and effectiveness of commonly prescribed medicines—a concept known as pharmacogenetics. This study aimed to quantify members of the UK public's preferences for a pharmacogenetic service to be delivered in primary care in the National Health Service.

Methods

Members of the UK population were surveyed via an online panel company. Respondents completed 1 of 2 survey versions, asking respondents to select their preferred pharmacogenetic testing service in the context of a presentation of low mood or pain. A conditional logit model was estimated, before the best functional form for the dataset was identified. Preference heterogeneity was identified via latent class analysis. Coefficients from the final selected models were used to estimate uptake in the context of different hypothetical pharmacogenetic services.

Results

Responses from 1993 individuals were included in the analysis. There were no differences observed in preference between the 2 clinical scenarios. Conditional logit analysis, using maximum likelihood estimation, indicated that respondents preferred to have noninvasive tests and wanted their data to be shared between different healthcare organizations to guide future prescribing. There was a preference for regional over national data sharing initiatives, and respondents preferred to have access to their data. Predicted uptake varied considerably, ranging from 51% to >99%, depending on design of the service.

Conclusion

This study identifies public preferences for a pharmacogenetic testing service and demonstrates how predicted uptake can be impacted by relatively minor adaptations. This highlights areas for prioritization during development of future pharmacogenetic services.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingState MedicineHumansMaleFemaleUnited KingdomAdultMiddle AgedAgedSurveys and QuestionnairesYoung AdultPatient PreferenceAdolescentChoice BehaviorPharmacogeneticsPrimary Health Care

Stichwörter der Autor:innen

geneticspharmacogeneticspharmacyprescribing

Autor:innen und Institutionen

  • Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Division of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester, UK.
  • Division of Informatics, Centre for Health Informatics, Imaging and Data Science, School of Health Sciences, The University of Manchester, Manchester, UK.
  • Centre for Primary Care and Health Services Research, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Manchester, UK.
  • Manchester Centre for Health Economics, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Manchester, UK.

ORCID-Profile: John H McDermott

Förderung

  • Wellcome Trust
  • Innovate UK
  • National Institute for Health and Care Research
  • Manchester Biomedical Research Centre

Zitieren

APA

McDermott, J. H., Sharma, V., Newman, W. G., Wilson, P., Payne, K., & Wright, S. (2024). Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs. British Journal of Clinical Pharmacology, 90(7), 1699-1710. https://doi.org/10.1111/bcp.16058

Vancouver

McDermott JH, Sharma V, Newman WG, Wilson P, Payne K, Wright S. Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs. British Journal of Clinical Pharmacology. 2024;90(7):1699-1710. doi:10.1111/bcp.16058

BibTeX
@article{McDermott2024,
  author = {McDermott, John H and Sharma, Videha and Newman, William G and Wilson, Paul and Payne, Katherine and Wright, Stuart},
  title = {Public preferences for pharmacogenetic testing in the NHS: Embedding a discrete choice experiment within service design to better meet user needs},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  volume = {90},
  number = {7},
  pages = {1699--1710},
  doi = {10.1111/bcp.16058}
}
Kostenlos starten →